Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Ocular Therapeutix ( (OCUL) ) has provided an update.
On February 11, 2025, Ocular Therapeutix’s Board of Directors approved a new compensation package for Pravin Dugel, M.D., reflecting his expanded roles as Chairman, President, and CEO since April 2024. The package includes an increased annual salary, bonus, and significant long-term equity awards tied to stock performance, aligning Dugel’s interests with shareholders and incentivizing company growth. This strategic move underscores Ocular Therapeutix’s commitment to rewarding leadership and performance, potentially enhancing its competitive edge in the biopharmaceutical sector.
More about Ocular Therapeutix
Ocular Therapeutix, Inc. operates in the biopharmaceutical industry, focusing on developing and commercializing therapies for eye diseases. The company is known for its innovative drug delivery systems and treatments aimed at addressing unmet medical needs in ophthalmology.
YTD Price Performance: -14.42%
Average Trading Volume: 916,714
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $1.18B
For detailed information about OCUL stock, go to TipRanks’ Stock Analysis page.
